血清胰岛素样生长因子-1和胰岛素样生长因子结合蛋白-3水平与胰腺癌及大肠癌发生风险相关性的Meta分析

目的评价血清中胰岛素样生长因子-1(insulin-like growth factor 1,IGF-1)、胰岛素样生长因子结合蛋白-3(IGF bonding protein 3,IGFBP-3)水平和胰腺癌及大肠癌发生的关系。方法利用Meta分析法对20个关于血清IGF-1、IGFBP-3水平与胰腺癌、结肠癌及直肠癌的巢式病例对照研究进行综合分析。结果胰腺癌研究中,IGF-1合并OR值为1.07(95%CI:0.81~1.43),IGFBP-3合并OR值为1.00(95%CI:0.76~1.30);结肠癌研究中,IGF-1合并OR值为1.31(95%CI:1.07~1.59),IGFBP-3合并OR值为1.08(95%CI:0.90~1.30);直肠癌研究中,IGF-1合并OR值为0.85(95%CI:0.55~1.30),IGFBP-3合并OR值为0.88(95%CI:0.59~1.32)。结论血清IGF-1及IGFBP-3水平与胰腺癌和直肠癌的相关性无统计学意义;血清中高水平的IGF-1增加结肠癌发生的风险性,但是不存在IGFBP-3水平改变影响结肠癌发生的证据。     

先天性甲状腺功能减低患儿胰岛素样生长因子及其结合蛋白的变化

【目的】观察先天性甲状腺功能减低(CH)新生儿及经替代治疗的CH患儿血清中胰岛素样生长因子．1(IGF-1)及胰岛素样生长因子结合蛋白-3(IGFBP-3)的变化。【方法】收集22例CH新生儿、21例替代治疗后的CH患儿静脉血清，采用放射免疫分析法(RIA)测定ICF-1水平，免疫放射分析法(IRMA)测定IGFBP-3水平，并与20例正常新生儿做对照。【结果】与正常新生儿组比较，CH新生儿血清IGF-1和IGFBP-3水平显著降低；替代治疗1～6月后，CH患儿血清IGF-1和IGFBP．3水平较CH新生儿明显升高。各组内IGF-1与IGFBP-3呈正相关，CH新生儿血清IGF-1和IGFBP-3水平与T4、TSH无明显相关性。【结论】CH患儿治疗前血清中IGF-1和IGFBP-3水平明显降低，替代治疗后水平升高。     

婴幼儿轮状病毒腹泻危险因素的病例对照研究

目的研究婴幼儿轮状病毒腹泻的影响因素。方法按1：1配对原则，分别选取74例社区对照和63例医院对照进行多重病例对照研究。结果母乳喂养期在6个月以内的婴儿(OR=0．147，95％CI=0．028～0．764)、住房的面积大(OR=0．22．95％CI：0．09～0．54)感染轮状病毒的危险性较小；但12个月后更长时间的母乳喂养(OR=3．278，95％CI：1．554～6．931)、母亲年龄较小(OR=41．89，95％CI：2．56～68．6；OR=12．77，95％CI：1．58～103)、老人看护(OR=11．39，95％CI：2～65．31)、经常抱孩子外出(OR=2．676，95％CI：1．042～6．821)会增加轮状病毒腹泻的感染率。结论母乳喂养在一定程度上可减少婴儿轮状病毒腹泻的发生，但喂养时间不宜过长；与外界环境接触机会增多。可能是导致轮状病毒腹泻的主要危险因素。     

吸烟对不同收入人群慢性病患病的影响

目的探讨吸烟对不同经济状况人群的健康影响。方法采用多阶段分层整群随机抽样的方法，在全国共抽取95个县、950个村(居委会)，每个样本村(居委会)随机抽取60户家庭，全国共抽取55200户家庭中15～65岁男性5．93万人。结果研究发现在控制年龄、经济状况、文化程度、就业状况、工作岗位的情况下，不论农村、城镇，与从不吸烟的人相比，有吸烟史的人群慢性病患病率均高(农村OR=1．185，95％CI：1．121～1．253；城镇OR=1．083，95％CI：1．010～1．161)；吸烟对农村男性患慢性病的影响(戒烟OR=2．764，95％CI：2．471～3．092)要大于城镇的相应人群(戒烟OR=2．112，95％CI：1．844～2．419)；另外发现吸烟对低收入人口患慢性病的影响(城镇OR=2．076，95％CI：1．551～2．780；农村OR=2．903，95％CI：2．248～3．749)大于对高收入人口的影响(城镇OR=1．785，95％CI：1．285～2．479；农村OR=2．466，95％CI：1．941～3．134)。结论吸烟对收入低下的人群健康损害更大，应该引起重视。     

不同避孕方法与育龄妇女贫血关系的现况研究

目的 了解江苏省农村育龄妇女的贫血状况并探讨不同避孕方法与贫血的关系。方法 资料来源于江苏省避孕药具不良反应监测点的基线调查，用非条件Logistic回归模型分析贫血的影响因素。结果 (1)江苏省农村育龄妇女的贫血患病率为42．54％。(2)贫血的危险因素为经济欠发达地区、年龄≥35岁(OR=1．125，95％CI：1．019～1．242)、月经周期≤24d(OR=1．489，95％CI：1．198～1．850)、多产次(OR=1．230，95％CI：1．125～1．346)、使用宫内节育器(OR=1．153，95％CI：1．047～1．269)；贫血的保护因素为：体重指数≥25kg／m^2(OR=0．693，95％CI：0．624～0．770)、非农民职业(OR=0．862，95％CI：0．776～0．957)、月经量少(OR=0．805，95％CI：0．744～0．871)。结论 农村育龄妇女的贫血患病率较高，已经成为严重的公共卫生问题；使用宫内节育器为贫血的影响因素．使用前应进行对象筛检。     

肝细胞癌合并肝硬化患者术后应用重组人生长激素联合肠外营养对生长激素/胰岛素样生长因子-1轴的影响

目的：探讨肝细胞癌合并肝硬化患者术后应用重组人生长激素（rhGH）联合肠外营养（PN）对生长激素（GH）／胰岛素样生长因子-1（IGF-1）轴的影响。方法：24例行根治性切除的肝癌患者随机分为PN组（n=12）和rhGH＋PN组（n=12）。术前、术后1d和6d测血清GH、IGF-1、IGFBP-3，用RT-PCR法检测肝组织（包括癌组织，癌旁组织和术后6d肝穿刺组织）IGF-1 mR-NA、IGFBP-3 mRNA的表达，肝组织行Ki67免疫组织化学染色。同时选12例因胆石症或肝血管瘤行手术的患者作为正常对照。结果肝细胞癌合并肝硬化患者血清GH水平高于正常对照组，而血清IGF-1、IGFBP-3水平低于正常对照组；术后6d，血清GH、IGF-1、IGFBP-3水平、肝组织IGF-1 mRNA、IGFBP-3m RNA表达水平、肝Ki67指数，rhGH＋PN组均高于PN组。PN组中位无瘤生存期是11．2个月，rhGH＋PN组中位无瘤生存期是11．4个月；PN组6个月、12个月无瘤生存率分别是71．1％、46.2％，rhGH＋PN组6个月、12个月无瘤生存率分别是72．2％、59、0％，差异均无统计学意义（P〉0.05）。结论：rhGH＋PN有利于改善肝细胞癌合并肝硬化患者术后GH／IGF-1轴。     

城市一般人群艾滋病相关知识、态度及其影响因素调查

目的 了解城市一般人群对艾滋病知识的认识、态度情况。以确定城市一般人群艾滋病知识水平及其影响因素，为今后在一般人群中采取针对性的艾滋病知识宣传策略提供依据。方法 于2002年12月1日在广州市商业区采用街头随机拦截的方式，对一般人群采用匿名自填问卷的方法调查其艾滋病相关知识和态度。结果 本次调查共发放问卷200份，收回有效问卷147份。结果显示，艾滋病知识总知晓率为63．3％；传播途径知识总知晓率为59．2％；预防知识知晓率为46．9％；对艾滋病感染／患正确态度率为49．7％。多因素Logistic回归分析显示，艾滋病知识知晓率的影响因素为年龄、性别、化程度和婚姻状况。30～39岁年龄组(OR=0．101，95％CI：0．015～0．678)和40岁及以上年龄组(OR=0．060，95％CI：0．007～0．498)艾滋病知识总知晓率低于15～20岁年龄组；女性艾滋病知识知晓率(OR=0．230，95％CI：0．099～0．532)低于男性；化程度初中(OR=14．161。95％CI：2．195～91．364)、高中(OR=23．455，95％CI：4．568～120．434)、大专以上(OR=35．378,95％CI:6．001～208．571)艾滋病知识知晓率高于小学及以下组；已婚(OR=5．761，95％CI：1．589～20．893)高于未婚。结论 目前城市一般人群的艾滋病知识水平仍然很低，因此应进一步加强对一般人群的艾滋病知识的宣传，尤其是针对化程度低、未婚及女性人群开展艾滋病知识的宣传教育。     

波生坦治疗肺动脉高压疗效与安全性评价的Meta分析

目的根据现有随机对照临床试验，综合评价波生坦治疗肺动脉高压的疗效与安全性。方法在数据库中检索以肺动脉高压患者为研究对象，并进行了波生坦治疗（治疗组）与安慰剂（安慰剂组）比较的随机对照试验（RCT）研究，对其短、长期疗效和安全性进行Meta分析。结果（1）有2项研究进行了短期疗效与安全性评价。与安慰剂组比较，治疗组患者：①min步行距离平均增加了47．71m（95％ CI 为26．09～69．33，P〈0．0001）；②WHO心功能分级改善率的合并比数比（OR）值为1．84（95％CI为1．06～3．18，P=0．03）；③呼吸困难明显改善，Borg呼吸困难评分平均下降0．71分（95％CI为0．19～1．23，P=0．007）；④病死率差异无统计学意义，其合并OR值为2．45（95％CI为0．28～21．35，P=0．42）；⑤肝损害的发生率差异无统计学意义，其合并OR值为1．78（95％a为0．66～4．81，P=0．26）；⑥临床病情恶化率明显改善，其合并OR值为0．26（95％CI为0．11—0．60，P=0．002）。（2）有2项研究评价了波生坦治疗的长期疗效与安全性：与安慰剂组比较，治疗组患者1年生存率明娃改善，其合并OR值为2．57（95％CI为1．59～4．17，P=0．0001）；肝损害的发生情况：2项研究均报道了治疗组患者转氨酶明显升高的病例，由于缺乏安慰剂组的资料，未对其进行Meta分析。结论波生坦治疗可以提高肺动脉高压患者的运动能力，改善心功能和呼吸困难的症状，提高患者1年生存率。肝损害可能是其主要副作用。     

耐亚胺培南铜绿假单胞菌致医院感染危险因素的病例对照研究

目的 探讨耐亚胺培南铜绿假单胞菌(IRPA)导致医院感染的危险因素。方法 选取2002年1月至2003年12月收治的67例IRPA医院感染病例、150例亚胺培南敏感铜绿假单胞菌(ISPA)医院感染者为病例组，同时选取同一病区，接受相似治疗措施的非铜绿假单胞菌感染的住院患者为对照组，其中敏感对照组159例，耐药对照组200例。分别对两组患者的危险因素进行病例对照研究，采用非条件logistic回归分析法进行分析。结果 多因素非条件logistic回归分析表明，IRPA医院感染的发生与住院时间长短(OR=1．03，95％CI：1．01～1．04)、亚胺培南(OR=4．65，95％CI：1．35～11．52)、哌拉西林／他唑巴坦(OR=3．37，95％CI：1．85～9．43)及喹诺酮类抗菌药物(OR=1．85，95％CI：1．25～5．34)的使用有关；而ISPA医院感染与三代头孢(OR=2．54，95％CI：1．26～5．23)及氨基糖苷类抗生素(OR=1．86，95％CI：1．42～3．26)的使用、住院时间长短(OR=1．05，95％CI：1．03～1．05)有关。结论 为减少IRPA医院感染的发生，在限制使用亚胺培南的同时，应尽可能根据药物敏感试验的结果，合理使用其他抗菌药物。     

ILIB启动子区多态性与癌症风险的meta分析

IL1B（Interleukin 1 beta）是一种对抗感染的前炎症因子，在肿瘤的发生发展中起着重要的作用。IL1B基因启动子区-31C／T多态性位点通过影响IL1B的转录参与癌症的发生。针对已有的研究存在结论不一致的现状，为了阐明两者之间的关系，我们对47篇发表的病例对照研究进行meta分析，其中包括11125病例和14415例对照。比值比（Odds Ratio，OR）和95％可信区间（CI）用来评估多态性位点与癌症风险的关联程度。在所有的对比中没有发现此多态性位点与所有癌症相关联。通过分层分析发现，携带C等位基因的个体比不带C等位基因的个体患肝癌的风险低（CCVS TT：OR=0．87，95％CI：0．77—0．98，Phetermgrenty=0．103；TC vs TT：OR=0．77，95％CI：0．62-0．95，Phetermgrenty=0．734；TC＋CC vs TT：OR=0．74，95％CI：0．61～0．91，Phetermgrenty=0．472）。同样，C／C基因型个体相比T，T基因型个体患胃癌风险低（OR=0．87，95％CI：0．77-0．98，Rhetermgrenty=0．103）。运用隐性模型，患胃癌的风险显著下降（OR=0．88，95％CI：0．80～0．97，Phetermgrenty=0．158），在欧洲人群（OR=0．84，95％CI：0．73-0．97,Phetermgrenty=0．070）和感染-配埘研究（OR=0．75，95％CI：0．60～0．94，Phetermgrenty=0．220）中都发现有显著下降的风险；在乳腺癌中有显著增加的风险（OR=1．34，95％CI：1．18～1．61，Phetermgrenty=0．116）。虽然一些适度偏倚不能消除，此meta分析显示IL1B-3IC基因型是癌症发生的保护因素，特别是在感染人群中。     

胰岛素样生长因子及其结合蛋白与妊娠期高血压疾病的相关性研究

目的:研究妊娠期高血压疾病患者血清胰岛素样生长因子-1(IGF-1)、胰岛素样生长因子结合蛋白-1(IGFBP-1)的水平与病情程度及新生儿出生体重之间的关系。方法:采用放射免疫方法测定并比较38例妊娠期高血压疾病患者与38例正常血压妊娠妇女的血清IGF-1、IGFBP-1的水平。结果:子痫前期组IGF-1显著低于妊娠期高血压组和正常组,而IGFBP-1水平显著高于妊娠期高血压组和正常组;妊娠期高血压组与正常组间IGF-1、IGFBP-1的水平比较,差异均无统计学意义。IGF-1水平与收缩压、舒张压及平均动脉压呈显著负相关,与新生儿出生体重呈显著正相关,而IGFBP-1与收缩压、舒张压及平均动脉压呈显著正相关,与新生儿出生体重呈显著负相关。结论:妊娠期高血压疾病患者的发病及严重程度与IGF-1、IGFBP-1有明显的关系,IGF-1、IGFBP-1与胎儿的发育及新生儿出生体重有明显的相关性。     

Markers of fetal growth and serum levels of insulin-like growth factor (IGF) I, -II and IGF binding protein 3 in adults

Fetal growth has been linked with increased risk of cancer and cardiovascular disease later in life. The insulin-like growth factor (IGF) axis has recently been proposed as a predictor of risk of subsequent cancer and cardiovascular disease. However, only few data are available on the possible association between fetal growth and levels of IGFs later in life. We examined the association between markers of fetal growth, i.e. birth weight, birth length and Ponderal Index, from birth records and serum IGF-I, IGF-II, and IGF binding protein 3 (IGFBP-3) levels in 545 middle-aged Danish men and women. We fitted separate multivariate models including birth weight, birth length, Ponderal Index and serum IGF-I, IGF-II, and IGFBP-3, respectively. After adjustment for age, alcohol intake, smoking, diabetes mellitus, systolic and diastolic blood pressure, serum total cholesterol and current height and weight, we found negative associations between birth weight and Ponderal Index, respectively, and serum IGF-II in men, i.e. the mean regression coefficients were -49.41 (95% CI: -87.06-11.77) (microg/l)/kg and -3.49 (95% CI: -6.73-0.25) (microg/l)/(kg/m3), respectively. Furthermore, in men birth weight was negatively associated with the (IGF-I + IGF-II)/IGFBP-3 and IGF-II/IGFBP-3 ratios, which are believed to be indicators of bioavailable IGF and IGF-II, respectively. However, no other associations were found in any of the models. Between 1 and 16% of the variance in serum IGF-I, IGF-II, and IGFBP-3, respectively, could be explained by the statistical models used in the analyses. We found very little support to the hypothesis of an association between fetal growth and the IGF axis throughout life.     

血清胰岛素样生长因子-1与高血压前期的联系

目的研究高血压前期与胰岛素样生长因子-1（IGF-1）之间的关系,探讨高血压的相关发病机制,从而为高血压的早预防、早诊断、早治疗提供新的思路和理论依据。方法采用自然抽样法选择天津市内六区的40—70岁常住居民非高血压390例为研究对象,根据血压水平分为高血压前期组（195例）与正常血压对照组（195例）,对其进行全面体检。采用酶联免疫吸附（ELISA）法测定两组的IGF-1水平,然后进行统计分析。结果高血压前期组IGF-1水平[（114．81±72．62）μg／L]明显高于正常血压对照组（99．48±62．08）wg／L],差异有统计学意义（t=2．241,P〈0．05）。logistic多元回归分析显示,IGF-1水平、性别、年龄和体质指数为高血压前期的相关独立危险因素[OR值分别为1．637（95％CI：1．056—2．536）、2．092（95％CI：1．213—3．607）、2．035（95％CI：1．469—2．821）和3．190（95％CI：2．052～4．958）,P〈0．05]。结论高血压前期患者的IGF-1水平升高,IGF-1可能参与了高血压前期的发生与发展。     

The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt

Insulin-like growth factor 1 (IGF-1) levels have been found to correlate with measurements of bone mineral density (BMD) in liver diseases. This study investigated the relationship between IGF-1, insulin-like growth factor binding protein 3 (IGFBP-3) and BMD in patients with chronic hepatitis C virus. This study was conducted for 30 patients with chronic hepatitis C virus infection (16 patients without and 14 patients with cirrhosis) and 11 healthy controls. Serum levels of IGF-1 and IGFBP-3 and BMD of the proximal femur and lumbar spine were measured in all subjects. Osteoporosis of the proximal femur and lumbar spine was found in 42.9% and 21.4%, respectively, of the patients with cirrhosis. Patients with liver cirrhosis and osteoporosis of the proximal femur and lumbar spine had lower IGF-1 (P < 0.001, P = 0.04, P = 0.04 respectively). BMD of the proximal femur was lower in cirrhotic patients compared with controls (P < 0.01). Patients with liver cirrhosis had lower IGFBP-3 than patients without cirrhosis and controls (P < 0.001). Patients with osteoporosis of the proximal femur had lower IGFBP-3 than those without osteoporosis (P < 0.01). IGF-1 and IGFBP-3 levels were lower in patients with liver cirrhosis. IGF-1 and IGFBP-3 may play a role in hepatic osteoporosis.     

非营养性吸吮对早产儿血清IGF-1、IGFBP-3及生长发育的影响

目的:探讨非营养性吸吮对早产儿血清IGF-1、IGFBP-3及生长发育的影响。方法:以2008年9月～2009年8月收治的早产儿60例为研究对象,随机分为非营养性吸吮(NNS)组和对照组,采用ELISA法测定生后第1天开奶前及生后第3天、第7天、第14天血清IGF-1、IGFBP-3水平,同时记录生长发育指标(头围、身长)。结果:①NNS组血清IGF-1、IGFBP-3水平在生后第7、14天高于对照组(P<0.05)。②与对照组相比,NNS组第14天头围、体重增长差异有统计学意义(P<0.01)。③血清IGF-1与头围、体重增长呈正相关(r=0.684,P<0.01;r=0.656,P<0.01),与血清IGFBP-3水平呈正相关(r=0.659,P<0.01)。结论:NNS能提高血清IGF-1、IGFBP-3水平,加快早产儿的生长发育。     

Reproducibility of assays for steroid hormones, prolactin and insulin-like growth factor-1 in umbilical cord blood

We assessed the reproducibility of measurements of plasma hormone and binding protein levels in umbilical cord blood collected from 30 male and female babies. They were delivered as singleton births from full-term pregnancies (gestational age >or= 37 weeks) in a cord blood donation programme. We assayed three plasma replicates from each cord blood sample at two points in time. Plasma oestradiol, unconjugated oestriol, testosterone, progesterone, prolactin, sex-hormone binding globulin (SHBG), insulin-like growth factor-1 (IGF-1), and IGF binding protein-3 (IGFBP-3) levels were measured in duplicates in the same batch (batch 1). In addition, another set of assays was conducted for each cord blood 1 year apart in a different batch (batch 2). Means and standard deviations for each hormone and binding protein were similar in replicates assayed in batch 1 and 2. Pearson's correlation coefficients were 0.9 or higher in duplicates assayed in batch 1. The correlation coefficients were between 0.77 and 0.96 for between-batch assays. Intra-class correlation coefficients (ICC) were higher than 0.9 for assay of SHBG [95% CI 0.92, 1.0] and progesterone [95% CI 0.87, 0.97] and between 0.8 and 0.9 for assay of oestradiol, unconjugated oestriol, prolactin, IGF-1, and IGFBP-3. The lowest ICC value was found for testosterone (ICC = 0.74; [95% CI 0.56, 1.0]). These data indicate a high reproducibility of cord blood hormone measurements; minimal differences were observed between the calibrated and the original regression coefficients for the association of hormones/binding proteins with percent of CD34+ cells in mononuclear cells.     

Insulin-like growth factor 1, insulin-like growth factor-binding protein 3, and testicular germ-cell tumor risk

Studies have consistently shown that taller men are at increased risk of testicular germ-cell tumors. Thus, it is plausible that factors associated with height may also influence risk of these tumors. The authors examined associations between testicular germ-cell tumor risk and circulating concentrations of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) among 517 cases and 790 controls from the US Servicemen's Testicular Tumor Environmental and Endocrine Determinants (STEED) Study (2002-2005). Odds ratios and 95% confidence intervals were estimated using logistic regression models, adjusting for age, race/ethnicity, height, and body mass index. All tests of significance were two-sided. Overall, there were no associations between IGF-1 or IGFBP-3 concentrations and risk of testicular germ-cell tumors (p > 0.05). However, when cases were separated by histologic type, there was a suggestion of a reduction in seminoma risk associated with the highest concentrations of IGF-1 as compared with the lowest concentrations (odds ratio = 0.66, 95% confidence interval: 0.40, 1.09). Although there were no overall associations with insulin-like growth factor, contrary to expectation, there was a suggestion that IGF-1 concentrations may be inversely associated with risk of seminoma.     

Isolated isoflavones do not affect the circulating insulin-like growth factor system in men at increased colorectal cancer risk

Epidemiological studies show that increased insulin-like growth factor (IGF)-I concentrations are related to increased colorectal cancer risk. A reduced colorectal cancer risk has been associated with isoflavones, which might affect the IGF-system because of their weak estrogenic activity. We conducted a randomized, placebo-controlled, double-blind crossover study to investigate the effect of an 8-wk isolated isoflavone supplementation (84 mg/d) on serum concentrations of total IGF-I, free IGF-I, total IGF-II, IGF binding protein (BP)-1, IGFBP-2, and IGFBP-3. Additionally, we investigated whether IGF-system component differences were related to concentrations of the more potent estrogenic isoflavone metabolite, equol. Our study population consisted of 37 men with a family history of colorectal cancer or a personal history of colorectal adenomas. Isoflavone supplementation did not significantly affect serum total IGF-I concentrations (relative difference between serum total IGF-I concentrations after isoflavone supplementation and after placebo: -1.3%, 95% CI -8.6 to 6.0%). Neither free IGF-I, nor total IGF-II, IGFBP-1, IGFBP-2, or IGFBP-3 concentrations were significantly altered. Interestingly, the change in serum IGF-I concentrations after isoflavone supplementation was negatively associated with serum equol concentrations (r=-0.49, P=0.002). In conclusion, isolated isoflavones did not affect the circulating IGF-system in a male high-risk population for colorectal cancer. However, to our knowledge, this is the first study that suggests isoflavones might have an IGF-I lowering effect in equol producers only. This underlines the importance of taking into account equol status in future isoflavone intervention studies.     

Dietary soy and fats in relation to serum insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 levels in premenopausal Japanese women

Circulating levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 (IGFBP-3) have each been associated with premenopausal breast cancer risks. We analyzed data from a cross-sectional study of 261 premenopausal Japanese women aged 20-54 yr with adequate nutritional status to evaluate the relationships between concentrations of IGF-1 and IGFBP-3 in serum and dietary intakes of soy, fats and other nutrients. Diet was assessed by a semiquantitative food frequency questionnaire. There was no significant correlation between soy product as well as soy isoflavone intake and serum IGF-1 or IGFBP-3 levels after controlling for age, total energy, percent body fat, and education level. Total fat intake was significantly inversely correlated with serum IGFBP-3 level (r = -0.13, P = 0.04). The correlations of saturated and monounsaturated fats with serum IGFBP-3 were of borderline significance (r = -0.12, P = 0.06 and r = -0.11, P = 0.07, respectively).     

Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men

Recent reports suggest that colorectal cancer is positively related to insulin-like growth factor I (IGF-I) and inversely related to insulin-like growth factor binding protein 3 (IGFBP-3). To evaluate these associations further and separately for colon and rectal cancer, the authors conducted a nested case-control study in a cohort of 9,345 Japanese-American men examined in Hawaii in 1971-1977. A total of 177 incident colon cancer cases and 105 incident rectal cancer cases were identified from 1972 to 1996. These patients' stored sera and those of 282 age-matched controls were measured for IGF-I and IGFBP-3. The adjusted mean level of IGF-I was higher in colon cancer cases than in controls (154.7 ng/ml vs. 144.4 ng/ml; p = 0.01). However, the multivariate odds ratio for the highest quartile compared with the lowest was just 1.8 (95% confidence interval: 0.8, 4.3). Adjusted mean IGF-I levels were similar between rectal cancer cases and their controls. For IGFBP-3, adjusted mean levels were lower for both colon and rectal cancer cases than for their matched controls, but the differences were not significant. The IGF-I results weakly support findings from other studies and suggest that there are differences in IGF-I findings between colon and rectal cancer cases. It is possible that IGF-related risk is confounded by other factors that may vary among different cohorts. Further research is needed to clarify these relations.